Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.
Daniel Tuyet KristensenRasmus Froberg BrøndumAndreas Due ØrskovClaus Werenberg MarcherClaudia SchöllkopfAnne Louise Tølbøll SørensenMarianne Tang SeverinsenMartin BøgstedAnne Stidsholt RougPublished in: European journal of haematology (2023)
Venetoclax-based salvage treatment for R/R AML produced high response rates; however, for most patients the response was of limited duration. This study is limited by an observational design and prone to selection bias.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute lymphoblastic leukemia
- peritoneal dialysis
- chronic lymphocytic leukemia
- prognostic factors
- diffuse large b cell lymphoma
- multiple myeloma
- squamous cell carcinoma
- cross sectional
- respiratory failure
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- drug induced
- combination therapy
- hodgkin lymphoma
- patient reported
- smoking cessation